NMPA Approves China's First Domestically Developed Implantable Cardiac Monitor (ICM)

Key Summary

On 1 July 2026, the National Medical Products Administration (NMPA) approved the registration application for an implantable cardiac monitor (ICM) from Suzhou Wushuang Medical Equipment Co., Ltd. The product is the first domestically developed ICM in China. It is intended to record subcutaneous electrocardiograms (ECG) in patients at increased risk of arrhythmia or with a confirmed arrhythmia diagnosis. The approval fills a gap in China's ICM field and is a landmark for domestic cardiovascular implant device companies. It highlights the need to consider the Special Review Procedure for Innovative Medical Devices, product classification determination, clinical evaluation requirements, and post-market surveillance obligations.

Source and Scope

Source: NMPA Medical Devices. Original date: 1 July 2026. Published on this site: 9 July 2026, 15:00. Source URL: https://www.nmpa.gov.cn/zhuanti/cxylqx/cxylqxlm/20260701094822157.html

This article is based on public information published by NMPA Medical Devices. Specific requirements remain subject to the latest official release by the regulatory authority.

Full Translation of Core Content

The National Medical Products Administration (NMPA) recently approved the registration application for an implantable cardiac monitor (ICM) from Suzhou Wushuang Medical Equipment Co., Ltd.

The product consists of an implantable cardiac monitor (ICM) and a patient trigger. It is used to record subcutaneous electrocardiograms (ECG) and is indicated for patients with clinical symptoms or a history of transient symptoms who are at increased risk of arrhythmia or have been diagnosed with arrhythmia.

This is the first domestically developed implantable cardiac monitor (ICM) product in China and fills the country's gap in the ICM field.

The drug regulatory authority will strengthen post-market surveillance of the product to protect patient safety in device use.

AIMEILI Regulatory Interpretation

The NMPA approval of Suzhou Wushuang Medical's ICM marks an important breakthrough in China's high-end active implantable medical device sector. For other domestic companies developing ICMs or similar cardiovascular monitoring devices, the case offers multiple reference points.

Registration pathway

The product is an innovative medical device and was most likely approved through the Special Review Procedure for Innovative Medical Devices, commonly known as the green channel. Companies should review the innovation determination criteria, application process, and communication mechanisms with the review authority. Overseas companies planning to introduce similar products into the Chinese market can also assess whether their products meet the definition of an innovative medical device to potentially accelerate registration.

Technical documentation and clinical evaluation

As an active implantable device, an ICM requires comprehensive verification data, including biocompatibility, electromagnetic compatibility (EMC), reliability, and wireless communication performance. Clinical evaluation may need to be supported by clinical trials or an equivalence comparison pathway. This approval indicates that, in the ICM field, the Chinese regulatory authority accepts evaluation based on domestic clinical data. Companies should plan clinical protocols in advance, including sample size, follow-up duration, and primary endpoints.

Quality management system

Active implantable devices are subject to stringent production quality management system requirements and must comply with the Medical Device Production Quality Management Practices and relevant appendices. Companies should establish a full-process system covering design and development, procurement, production, inspection, and post-market surveillance. Traceability and recall mechanisms for implantable devices are particularly important regulatory focus areas.

Labeling, instructions for use, and post-market obligations

ICM products must clearly state indications, contraindications, precautions, and electromagnetic environment compatibility information. The regulatory authority will strengthen post-market adverse event monitoring and re-evaluation. Companies need effective complaint handling and periodic risk analysis mechanisms. For export, products must also meet requirements in target markets such as the U.S. FDA and the EU MDR, including CE marking, PMA, or 510(k), as applicable.

Business Impact

For global medical device manufacturers, distributors, CROs, and regulatory affairs teams, this approval should be treated as more than routine news. It should be classified as a product approval update and assessed for its impact on product classification, registration pathway, applicant structure, local agent responsibilities, and certificate maintenance arrangements.

Companies with active China registration projects should add this update to their regulatory tracking table and assess whether it affects product classification, clinical evaluation strategy, technical documentation, labeling, or post-market obligations. The approval also provides a useful benchmark for evaluating the evidence expected for active implantable cardiovascular monitoring devices in China.

Companies should prioritize a review of the intended use, classification basis, ISO 13485 quality management system certificate, risk management file, performance verification data, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents, and existing registration certificates.

• Common risks include unclear classification determination, an incomplete evidence chain, non-localized labels and instructions for use, unclear authorized representative responsibilities, and insufficient post-market maintenance arrangements.
• For China-based manufacturers, the immediate impact is likely to be seen in dossier consistency and evidence-chain management.
• If the update concerns safety notices, recalls, product approvals, or regulatory meetings, companies should also assess whether similar products, technologies, or risk profiles may receive increased review attention.

AIMEILI recommends three practical actions: first, record the official source link, publication date, applicable product scope, and potentially affected areas in the regulatory tracking log; second, have regulatory, quality, R&D, and sales teams jointly determine whether labels, instructions for use, clinical evaluation, risk management, or test reports need updating; third, if the product is already marketed locally or a registration application has been submitted, assess whether the local agent, importer, distributor, and after-sales team need to take communication, change notification, supplementary explanation, or post-market surveillance measures.

The value of this type of news lies in converting public information into executable compliance actions. Companies preparing multi-country registrations should pay particular attention to the boundaries of dossier reuse: the same CE, FDA, NMPA, ISO 13485, or MDSAP documentation may serve as core evidence in one country but require localized explanations, language-specific labeling, authorized representative documents, or post-market maintenance plans in another. AIMEILI recommends a short documentation gap review after each significant regulatory update to avoid passive corrections, changes, or renewal issues later.

FAQ

Can this 1 July 2026 ICM approval be used directly as a basis for a registration application? No. This article is intended for preliminary understanding and project assessment. A formal application must be based on the latest requirements of the target country's regulatory authority, the product classification conclusion, and the company's actual documentation.

What should companies do first after seeing this update? Conduct a documentation gap assessment to confirm whether the update affects the registration pathway, technical file, labeling, quality management system, or post-market maintenance.